Skip to main content

The Fourth Xarelto Trial moved to Early 2018

The Fourth Xarelto Trial moved to Early 2018

The Fourth Xarelto Trial moved to Early 2018

Introduction

Just when hopes were running high on the fourth Xarelto trial scheduled to begin this October in the US District Court ND Texas, we are informed that it has been postponed until early 2018. The verdicts for the three previous lawsuits went in favor of the defendants Johnson & Johnson's Janssen Pharmaceuticals and Bayer; however, expectations are pinned on this fourth trial as it represents circumstances which are quite different from the previous cases and could bring in a positive verdict for the plaintiff. Thousands of lawsuits have been filed against the defendants due to its severe side-effects including serious internal bleeding. Allegations involve failure to warn the patients and medical community about the associated risks. Xarelto lawsuits are consolidated under MDL 2592 in the US District Court for the Eastern District of Louisiana under Judge Eldon Fallon, and more than 18,000 lawsuits are pending in courts across the country. This delay may bring in settlement news between the defendants and plaintiffs.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!